Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Neratinib|DRUG: Trastuzumab|DRUG: Paclitaxel
Sponsor: Puma Biotechnology, Inc.